Search
Molecular Partners AG
MOLNAdd to Watchlist
2.940USD
-0.070-2.33%
Close 11-13 16:00（ET）
109.95MMarket Cap
LossP/E TTM
Molecular Partners AG (MOLN) Stock Price Target & Forecast
Analyst Rating
Based on 6 analysts giving stock ratings to Molecular Partners AG in the past month.
Buy
1 Strong Buy
4 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
11.600USD+224.02%
MOLN Analyst Recommendation Trends
In the current month, MOLN has received 4 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. MOLN average Analyst price target in the last month is 11.600.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
1
1
1
1
1
1
1
1
4
4
3
3
3
3
3
3
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6
6
5
5
5
5
5
5
MOLN Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ascendis Pharma A/S
ASND
9
13
1
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
Based on analysts' estimates, MOLN EPS is projected to reach -0.401 in FY2026Q3, following reported EPS of -0.438 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.35
-0.40
-0.42
-0.40
-0.43
Actual
-0.42
-0.44
-0.44
--
--
Surprise
-19.83%
-10.84%
-4.53%
--
--
FAQs
What is Molecular Partners AG's price target?
Analysts forecast that Molecular Partners AG's price target is USD 11.60, with the highest forecast at USD 17.00 and the lowest forecast at USD 8.00.
How have Molecular Partners AGMOLN's recent earnings per share performed?
The market expectation was USD -0.44, while Molecular Partners AGMOLN's earnings per share (EPS) for the previous quarter was USD -0.44. EPS for the next quarter is expected at USD -0.40.
What is the analyst rating for Molecular Partners AG?
Based on the ratings of Molecular Partners AG's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.